NEW YORK, August 17, 2026, 16:00 EDT
- INVO Fertility closed at $1.53, up 60.38%, after touching $2.80.
- Volume reached 113.75 million shares, about 1,513 times the prior 20-session average.
- The latest filed quarter showed 23% revenue growth but a wider operating loss.
INVO Fertility NASDAQ:IVF shares jumped 60.38% on Monday as trading volume exploded to 113.75 million shares. The stock closed at $1.53 after reaching $2.80, according to Yahoo Finance market data.
The close carried the sharper investor signal. Shares finished 45.4% below their intraday high and 32.0% below the opening price. Buyers won the day, but late holders absorbed a steep reversal.
The Nasdaq market is now closed. No new company announcement or SEC filing explaining the surge was identified by publication time. That leaves trading mechanics, rather than disclosed operating news, as the clearest immediate driver.
| Monday trading marker | Price | Change versus prior close |
|---|---|---|
| Prior close | $0.954 | — |
| Open | $2.25 | +135.8% |
| Intraday high | $2.80 | +193.5% |
| Intraday low | $1.4097 | +47.8% |
| Close | $1.53 | +60.38% |
Volume was the outlier. Monday’s turnover exceeded the previous five-session average by about 2,226 times. It topped the prior 20-session average by roughly 1,513 times.
| Volume comparison | Shares | Monday multiple |
|---|---|---|
| Monday, August 17 | 113,750,838 | 1.0x |
| Prior five-session average | 51,100 | 2,226x |
| Prior 20-session average | 75,200 | 1,513x |
Related fertility names did not confirm a broad sector rally. Progyny (NASDAQ:PGNY) fell 3.6%, while CooperCompanies NASDAQ:COO lost 1.4%. INVO’s move was company-specific in price action, even without a disclosed catalyst.
| Company | Monday close | Daily move | Business exposure |
|---|---|---|---|
| INVO Fertility NASDAQ:IVF | $1.53 | +60.38% | Fertility clinics and INVOcell |
| Progyny (NASDAQ:PGNY) | $25.33 | -3.6% | Employer fertility benefits |
| CooperCompanies NASDAQ:COO | $75.10 | -1.4% | Fertility and women’s-health products |
The operating picture is less dramatic. First-quarter revenue rose 23% to $2.02 million. Yet the operating loss widened 33% to $1.59 million, while adjusted EBITDA fell to negative $1.26 million.
| Quarter ended March 31 | 2026 | 2025 | Year-on-year change |
|---|---|---|---|
| Revenue | $2.02 million | $1.64 million | +23% |
| Operating loss | $1.59 million | $1.20 million | +33% |
| Adjusted EBITDA loss | $1.26 million | $0.61 million | +108% |
| Cash, period end | $4.90 million | $0.84 million | +484% |
Cash improved after financing. Still, current liabilities stood at $6.36 million on March 31. Management said continued losses and reliance on new capital raised substantial doubt about its ability to continue as a going concern.
Dilution remains central. INVO issued more than 1.16 million common shares during the first quarter through warrant exercises, preferred conversions and compensation. It also had 2.05 million potentially dilutive warrants excluded from diluted-share calculations.
Reverse splits amplify the caution. INVO completed 1-for-3, 1-for-8 and 1-for-5 reverse splits between July 2025 and March 2026. Combined, those actions equal a 1-for-120 consolidation.
The growth case rests on clinics. INVO bought Indiana-based Family Beginnings for $760,000 in February. The clinic generated about $1 million of revenue and $0.2 million of net income during the first nine months of 2025.
Its Wisconsin clinic also joined Progyny’s network in March. Chief Executive Steve Shum said the relationship expands the addressable patient base and access to employer-sponsored demand. The commercial benefit has not yet been quantified.
Published analyst coverage is thin and internally inconsistent. That makes headline price targets less useful than cash generation, financing terms and share-count changes.
| Analyst or tracker | Recommendation | Price target | Coverage note |
|---|---|---|---|
| Maxim Group | Buy | $4.00 | February 10, 2026 action |
| Investing.com poll | Buy | $20.00 average | One analyst; page also lists Maxim at $4 |
| MarketBeat consensus | Moderate Buy | $20.00 average | One strong buy and one sell |
For the week ahead, investors should watch whether volume normalizes and whether INVO files fresh disclosure. A close above Monday’s $2.80 high would show renewed demand. Failure to hold $1.41 would erase the session’s lowest support.
Risks: INVO is a micro-cap with extreme volatility, limited analyst coverage and recurring financing needs. Thin historical liquidity, potential dilution and Nasdaq compliance actions can overwhelm clinic-level progress.
Related articles: Stock Market
